0001193125-13-149261.txt : 20130410 0001193125-13-149261.hdr.sgml : 20130410 20130410161018 ACCESSION NUMBER: 0001193125-13-149261 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20130404 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130410 DATE AS OF CHANGE: 20130410 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATUS MEDICAL INC CENTRAL INDEX KEY: 0000878526 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 770154833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-33001 FILM NUMBER: 13753881 BUSINESS ADDRESS: STREET 1: 1501 INDUSTRIAL ROAD CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 6508020400 MAIL ADDRESS: STREET 1: 1501 INDUSTRIAL ROAD CITY: SAN CARLOS STATE: CA ZIP: 94070 8-K 1 d519790d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported): April 4, 2013

 

 

Natus Medical Incorporated

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-33001   77-0154833

(State or other jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

1501 Industrial Road

San Carlos, CA 94070

(Address of principal executive offices)

650-802-0400

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On April 4, 2013, Natus Medical Incorporated (the “Company”) received a notice from The Nasdaq Stock Market LLC stating that because the Company had not yet filed its Annual Report on Form 10-K for the year ended December 31, 2012 (the “2012 Annual Report”), the Company no longer complied with the Nasdaq listing requirements and specifically with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires that listed companies timely file all required periodic financial reports with the Securities and Exchange Commission (the “Commission”).

In a Form 12b-25 Notification of Late Filing filed by the Company with the Commission on March 18, 2013, the Company had reported that while its 2012 Annual Report could not be filed by the prescribed due date of March 18, 2013, the Company expected to file the 2012 Annual Report on or before April 2, 2013, which was the extended due date under Rule 12b-25. The Company was not, however, able to file the 2012 Annual Report within the extended filing period.

On April 10, 2013, the Company filed the 2012 Annual Report with the Commission and, by making such filing, has regained compliance with the Nasdaq listing requirements and specifically with Nasdaq Listing Rule 5250(c)(1).

On April 10, 2013, the Company is issuing a press release announcing the filing of the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission, the receipt of the notice from the Nasdaq Stock Market LLC, and other information.

 

Item 9.01 Financial Statement and Exhibits

(d) Exhibits.

 

Exhibit No.

   

Description

99.1    Press release dated April 10, 2013 announcing the filing of the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission, the receipt of the notice from the Nasdaq Stock Market LLC, and other information.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

NATUS MEDICAL INCORPORATED

(Registrant)

Dated: April 10, 2013     By:   /s/ Jonathan A. Kennedy
     

Senior Vice President and Chief Financial Officer

     

Exhibit Index

 

Exhibit No.

   

Description

99.1    Press release dated April 10, 2013 announcing the filing of the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission, the receipt of the notice from the Nasdaq Stock Market LLC, and other information.
 EX-99.1 2 d519790dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Natus Files 2012 Form 10-K

- Cures Lack of Compliance Notice from Nasdaq

SAN CARLOS, Calif. (April 10, 2013) – Natus Medical Incorporated (Nasdaq:BABY) today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2012 (“Annual Report”) with the Securities and Exchange Commission (the “Commission”).

For the year ended December 31, 2012 the Company’s results reported in the Annual Report were marginally favorable relative to the amounts it reported on February 28, 2013, reflecting an increase in revenue of $581,000, an increase in net income of $263,000, and an increase in diluted earnings per share of $0.01.

The Company also announced that it received a notice from the Nasdaq Stock Market on April 4, 2013 stating that the Company was not in compliance with the continued listing requirements under Nasdaq Rule 5250(c)(1), because it had not filed its Annual Report. With the filing of its Annual Report on April 10th, Natus is again compliant with Nasdaq listing requirements.

About Natus Medical Incorporated

Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories.

Additional information about Natus Medical can be found at www.natus.com.

COMPANY CONTACT:

Natus Medical Incorporated

Jonathan Kennedy

Senior Vice President and Chief Financial Officer

(650) 802-0400

InvestorRelations@Natus.com

GRAPHIC 3 g519790p5a.jpg GRAPHIC begin 644 g519790p5a.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!X17AI9@``24DJ``@````&`#$!`@`1 M````5@````$#!0`!````:`````,#`0`!`````/>D"1!1`0`!`````0```!%1 M!``!````Q`X``!)1!``!````Q`X```````!-:6-R;W-O9G0@3V9F:6-E``"@ MA@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H< M'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T- M&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R M,C(R,C(R,C(R,O_``!$(`#<`UP,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0`` M`````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$% M$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U M-CH.$A8:'B(F* MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G: MX>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(# M!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q M$R(R@0@40I&AL<$)(S-2\!5B7J"@X2%AH>(B8J2DY25EI>8 MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/?Z*Q?^$N\/_P#07M?^^Z/^$N\/ M_P#07M?^^ZOV<^QC]8H_SK[T;5%8O_"7>'_^@O:_]]UHHJK?ZC::7;?:;V=88C>HK!_X33PY M_P!!:#]?\*TK#5;#5$+V-W#<`=?+8$CZCM2<)+5HJ->E-VC)-^IUCZ?VD.7GNK=R]163:^)]$O M;F.VMM2@EFD.%13R36M0TUN$*D9J\7<**K7U_:Z;;&YO)TAA!`+OTR>E9T?B M[0)9%C35;=G'TT,2 M3D&Z@;RY2/XO1OQ']:C\?65U?^&6@L[>2>7SD.R-PM\5@DIO=6_0\%_P"$6U[_`*`]Y_WZ-'_"+:]_T![S_OT: M]AN_%>A6,QAN-3@60<%5);'Y9JO_`,)QX;_Z"D?_`'PW^%="Q-5_9/,>58-. MSJ_BCQ^[T+5K&$S76G7,,0ZN\9`'XU!87]SIEY'=VQ7'C/ MPQ<6TL,FHQNDBE64HV""/I7BAZ\=*Z*4Y5$U-6/.QN'IX:471GS?I]Q[M#>G MQ!X/:Y@3]Y0>AZUA]J]_\/?\BYIO_7M'_P"@BNK$5732:/%RW!0Q M4Y1FVK=C$^'^DWVD:/P2@ATF<'/UZUC@X MIR;9W9Y4G&E&,=F]2*TL+R_=DL[6:=E&2(D+8_*K?_".:W_T";W_`+\FNN\` M>)])TC3I[._D%O(TOF"0J2'&`,<>F/UKL/\`A./#?_04C_[Y;_"MZE>I&32B M>?AL!A:M)3G5LWTT/(?^$E@LMH M4ZJJTZG-;T%HHHKD/:/FZO9OAU_R)\'_`%TD_P#0J\9KV;X=?\B?!_UTD_\` M0J]/&?P_F?)9'_O+]'^:.KKPKQC_`,C=J?\`UV_H*]UKPKQC_P`C=J?_`%V_ MH*PP7QOT/1S[^!'U_1G8_"G_`(]M3_WX_P"358^(_B&>PMX=+M)#')<*7E=3 M@A.F!]>?RJO\*?\`CVU/_?C_`)-69\4;22/6[6Z(/E2P;`>V5)R/U%5RIXEW M_K0Q]I.&5)P_K5G'Z=IMWJMZEI90F69^@'&!ZD]A71_\*X\0_P#/*W_[_"JG M@S7X/#^M-<72,T$L9C=E&2O(.?TKT?\`X6%X;_Y_7_[\M_A6M:I5C*T%H<>! MPV#JT^:M.S]4C@S\./$(!)2V_P"_W_UJY(\'%>T-\0/#A4C[:W(_YXM_A7C! MY)^M70G4E?G5C+,*&&I5[WOK?L>S_#S_`)$VU_WY/_0C6CXJ_P"14U3_ M`*]V_E6=\//^1-M?]^3_`-"-:_B"V>[\/:A;Q#+O;N%'J<=*\^?\9^I])03> M!BE_+^AX!VKW_P`/?\BYIO\`U[1_^@BO`*],\.?$/3K31K>SU&.9)H$$8:-- MP8#H?8XKMQ4)3BN5'@Y-B*=&I+VCM='HM>9253!2E! MW6GYG&^#/^1PTW_KJ?\`T$U[G7SUI6H/I6JVU]&H9H'#;3W'>)/^?2+_`+_K_C7HG_">>&O^@D/^_3_X4?\`">>&O^@D M/^_3_P"%=7MZ_P#+^#/'_L_+O^?G_DR/(-5T:_T6Y%O?VYB=AE>00P]B*[+X M;^(9H[[^QKB0O!(I,&X_<8FM8;#+Q0;B92N-Q..!GG'%9 M_@>$R>*K:8D+%;!II7/`50IY)_&MY7G1;FM3SJ35#'*-"5U=+Y=3V^BLZQUN MPU"?R;>5M^W^)/^?*/_`+_I_C7I M7@W3+O2/#D5G>QB.=7GUKH=:T6TUW3GL[M3M/*NOWD;U%%%*524I<_4JEA MJ=.C['>/F>:W?PQUB*8BUGMIXNS,Q0_B,57_`.%;>(?[MK_W^_\`K445LL74 M.%Y+A6[Z_>)_PK?Q#_SSMO\`O]_]:C_A6_B'_GG;?]_O_K444_K=0G^Q,+Y_ M?_P#TCPCI=SHWAV"RO`@F1G)"-D>>)?A MR]W=R7FCR1H9#N>WD.!GN5/;Z5S/_"O?$G_/G'_W_3_&BBNB.*J15CSJN3X: MI)RU5^QW_@/1+_0]*N8-0B6.1Y]Z@.&XV@=OI70ZA86VJ6,MG=Q[X91AA_4> M]%%8RFY2YNIW4J$*=)4EJEW/+]1^&6JPSM]@FAN82?EWML8#W[52_P"%=>(_ M^?>#_O\`"BBMUBZB/.EDN%;NKKYA_P`*Z\1_\^\'_?X5/8_#_P`00:A;3200 M!(Y59L3#H"#110\74?8%DN&3O=_?_P``]?KRK7?`>N7^NWUW!'`8IIF="90# M@T45C3JRIN\3MQ6$IXJ*C4Z%#_A7'B+_`)Y6_P#W^%'_``KCQ%_SRM_^_P`* M**V^N5#A_L3#>?W_`/`'P_#77I)`LGV6)>[&7./P`KN-/\%V^E^'[NQMY`]W M(G/BVXJ[\QND:+>QZM%